We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
ALDH1: A potential therapeutic target for cancer stem cells in solid tumors.
- Authors
Yaolu Wei; Yan Li; Yenan Chen; Pei Liu; Sheng Huang; Yuping Zhang; Yanling Sun; Zhe Wu; Meichun Hu; Qian Wu; Hongnian Wu; Fuxing Liu; Tonghui She; Zhifeng Ning
- Abstract
Solid tumors can be divided into benign solid tumors and solid malignant tumors in the academic community, among which malignant solid tumors are called cancers. Cancer is the second leading cause of death in the world, and the global incidence of cancer is increasing yearly New cancer patients in China are always the first. After the concept of stem cells was introduced in the tumor community, the CSC markers represented by ALDH1 have been widely studied due to their strong CSC cell characteristics and potential to be the driving force of tumor metastasis. In the research results in the past five years, it has been found that ALDH1 is highly expressed in various solid cancers such as breast cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer, cervical cancer, esophageal cancer, ovarian cancer, head, and neck cancer. ALDH1 can activate and transform various pathways (such as the USP28/MYC signaling pathway, ALDH1A1/HIF-1a/VEGF axis, wnt/b-catenin signaling pathway), as well as change the intracellular pH value to promote formation and maintenance, resulting in drug resistance in tumors. By targeting and inhibiting ALDH1 in tumor stem cells, it can enhance the sensitivity of drugs and inhibit the proliferation, differentiation, and metastasis of solid tumor stem cells to some extent. This review discusses the relationship and pathway of ALDH1 with various solid tumors. It proposes that ALDH1 may serve as a diagnosis and therapeutic target for CSC, providing new insights and new strategies for reliable tumor treatment.
- Subjects
CHINA; CANCER stem cells; ESOPHAGEAL cancer; HEAD &; neck cancer; BENIGN tumors; LIVER cancer; STEM cells; LUNG cancer
- Publication
Frontiers in Oncology, 2022, Vol 12, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2022.1026278